Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 9—September 2024
CME ACTIVITY - Research
Clinical Aspects and Disease Severity of Streptococcus dysgalactiae Subspecies equisimilis Bacteremia, Finland1
, Janne Aittoniemi, Reetta Huttunen, Tiina Luukkaala, and Sari Rantala
Table 2
Disease severity among 159 episodes of Streptococcus dysgalactiae subspecies equisimilis bacteremia during November 2015–November 2019, Finland*
| Characteristic | Total, n = 159 | Survivors, n = 150 | Nonsurvivors, n = 9 | p value |
|---|---|---|---|---|
| Admitted to intensive care unit |
11 (7) |
8 (5) |
3 (33) |
0.017 |
| Needed mechanical ventilation | 3 (2) | 2 (1) | 1 (11) | 0.161 |
| Needed continuous renal replacement therapy | 1 (1) | 1 (1) | 0 | NA |
| Needed hemodialysis | 1 (1) | 1 (1) | 0 | NA |
| Needed vasopressors |
15 (9) |
12 (8) |
3 (33) |
0.041 |
| Lowered level of consciousness† | 37 (23) | 31 (21) | 6 (67) | 0.005 |
| Unconscious |
7 (4) |
4 (3) |
3 (33) |
0.004 |
| Hypotension‡ | 36 (23) | 30 (20) | 6 (67) | 0.005 |
| Septic shock§ | 18 (11) | 13 (9) | 5 (56) | 0.001 |
| Disseminated intravascular coagulation¶ | 6 (4) | 5 (3) | 1 (11) | 0.299 |
| Multiorgan failure# |
12 (8) |
8 (5) |
4 (44) |
0.002 |
| Underwent surgical intervention | 38 (24) | 33 (22) | 5 (56) | 0.037 |
*Values are no. (%) except as indicated; p values compare survivors and nonsurvivors. NA, not applicable. †Lowered level of consciousness (unconscious or confusion) >1 time during the first 2 days after positive blood culture. ‡Systolic blood pressure <90 mm Hg >1 time during days 0–2 after positive blood culture. §Use of vasopressor and blood lactate level >2 mmol/L >1 time during days 0–2 after positive blood culture. ¶Platelet counts <100 × 109/L. #Observed >3 concomitant organ failures.
1Preliminary results from this study were presented at the European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2024; Barcelona, Spain.